Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIOP) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Fortress Biotech (FBIOP) over the last 13 years, with Q3 2025 value amounting to $100000.0.

  • Fortress Biotech's Depreciation and Depletion changed 0.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $466000.0, marking a year-over-year decrease of 6211.38%. This contributed to the annual value of $1.0 million for FY2024, which is 5336.32% down from last year.
  • Fortress Biotech's Depreciation and Depletion amounted to $100000.0 in Q3 2025, which was down 0.0% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Depreciation and Depletion registered a high of $844000.0 during Q1 2023, and its lowest value of $100000.0 during Q3 2024.
  • Its 5-year average for Depreciation and Depletion is $501000.0, with a median of $600000.0 in 2021.
  • As far as peak fluctuations go, Fortress Biotech's Depreciation and Depletion surged by 3333.33% in 2022, and later plummeted by 7500.0% in 2024.
  • Over the past 5 years, Fortress Biotech's Depreciation and Depletion (Quarter) stood at $728000.0 in 2021, then grew by 11.13% to $809000.0 in 2022, then plummeted by 59.21% to $330000.0 in 2023, then crashed by 57.58% to $140000.0 in 2024, then fell by 28.57% to $100000.0 in 2025.
  • Its Depreciation and Depletion was $100000.0 in Q3 2025, compared to $100000.0 in Q2 2025 and $126000.0 in Q1 2025.